Stock analysts at Oppenheimer Holdings, Inc. assumed coverage on shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX) in a research note issued to investors on Monday. The firm set an “outperform” rating and a $18.00 price target on the biotechnology company’s stock. Oppenheimer Holdings, Inc.’s price target would suggest a potential upside of 66.67% from the stock’s previous close.

A number of other brokerages also recently issued reports on MRTX. ValuEngine raised shares of Mirati Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday. Jefferies Group LLC reissued a “hold” rating and set a $4.50 price target on shares of Mirati Therapeutics in a report on Monday, June 12th. Finally, Leerink Swann upped their price objective on shares of Mirati Therapeutics from $7.00 to $9.00 and gave the stock a “market perform” rating in a research report on Friday. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and three have assigned a buy rating to the company. Mirati Therapeutics has an average rating of “Hold” and an average target price of $9.79.

Shares of Mirati Therapeutics (NASDAQ:MRTX) traded down 3.57% during mid-day trading on Monday, hitting $10.80. 8,676,581 shares of the stock traded hands. The stock’s market cap is $269.67 million. Mirati Therapeutics has a 12 month low of $2.70 and a 12 month high of $12.40. The firm has a 50 day moving average of $5.21 and a 200 day moving average of $4.48.

ILLEGAL ACTIVITY NOTICE: This piece was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/18/oppenheimer-holdings-inc-begins-coverage-on-mirati-therapeutics-inc-mrtx.html.

A number of large investors have recently bought and sold shares of MRTX. KCG Holdings Inc. acquired a new position in Mirati Therapeutics during the first quarter worth $106,000. Susquehanna International Group LLP raised its position in Mirati Therapeutics by 46.5% during the second quarter. Susquehanna International Group LLP now owns 50,509 shares of the biotechnology company’s stock worth $184,000 after acquiring an additional 16,030 shares during the period. PDT Partners LLC acquired a new position in Mirati Therapeutics during the second quarter worth $200,000. Trexquant Investment LP raised its position in Mirati Therapeutics by 62.2% during the first quarter. Trexquant Investment LP now owns 42,879 shares of the biotechnology company’s stock worth $223,000 after acquiring an additional 16,447 shares during the period. Finally, LMR Partners LLP acquired a new position in Mirati Therapeutics during the second quarter worth $236,000. Institutional investors own 60.17% of the company’s stock.

About Mirati Therapeutics

Mirati Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The company’s clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.

Analyst Recommendations for Mirati Therapeutics (NASDAQ:MRTX)

Receive News & Stock Ratings for Mirati Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics Inc. and related stocks with our FREE daily email newsletter.